Takeaways: Completing pCPA negotiations is a key step toward public reimbursement for Nemluvio in Canada, which—once provincial/territorial drug plans list it—should materially expand access for...
Takeaways: Roche’s pCPA win for Itovebi is a major reimbursement de-risking event in Canada, because it moves the drug much closer to broad public coverage after a ...
